The Swedish-British pharmaceutical company AstraZeneca achieved a net profit of 10,233 million dollars (8,597 million euros) in 2025, 45.3% more than in the previous year, it was announced this Tuesday, 10.
Revenues reached 58,739 million dollars (49,347 million euros), 8.6% more than in 2024, driven by the turnover of the oncology unit, which grew 15%, to 25,619 million dollars.
The biotechnology division generated 22,995 million dollars (19,318 million euros) and the rare diseases division generated 9,126 million dollars (7,667 million euros), 5% more and 4% more, respectively.
Revenue from other drugs reached 999 million dollars (839.3 million euros).
In the fourth quarter alone, profits increased 55.3%, to 2,329 million dollars (1,957 million euros), while revenue grew 4.1%, to 15,503 million dollars (13,024 million euros).
“In 2025 we saw a solid commercial performance in all our therapeutic areas and an excellent execution of our portfolio of products under development”, stated the executive president (CEO) of Astrazeneca, Pascal Soriot, who also highlighted that the company’s shares began to be traded on the New York Stock Exchange on February 2nd.
The company forecasts that revenues will increase in 2026 by between 6% and 9% and that earnings per share will increase just above 10%. A total dividend of 3.20 dollars (2.69 euros) was declared, which represents an increase of 3%.
Leave a Reply